Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib vs Chemotherapy in Refractory Advanced Biliary Cancer
NCT02042443Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trametinib in biliary tract cancer (BTC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 2 years. Started Feb 2014; status: completed.
02
Drugs
trametinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02042443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042443.